Inspire Medical Systems Revenue Guide Misses by 2.7%, Shares Drop 8.7%
Inspire Medical Systems’ shares slid 8.7% after its 2026 revenue guidance came in 2.7% below analyst expectations, despite a robust fourth-quarter earnings beat. The guidance miss stems from medical billing code clarifications for its Inspire V procedure, which are projected to reduce physician reimbursement and pressure adoption rates.
1. Q4 Earnings Outperform Estimates
In the fourth quarter, Inspire Medical Systems beat analyst forecasts for both revenue and profit, driven by continued strength in its hypoglossal nerve stimulation devices and sustained demand across major markets.
2. Full-Year Guidance Falls Short
For fiscal 2026, the company forecast revenue 2.7% below consensus, reflecting more cautious assumptions on procedure growth and volume than Wall Street anticipated.
3. Billing Code Clarifications Create Headwinds
Clarifications to Medicare billing codes for the Inspire V procedure are expected to lower physician reimbursement rates, potentially slowing adoption and reducing revenues per treatment.
4. Stock Drops on Weaker Outlook
Investors reacted to the guidance shortfall by sending shares down 8.7% in morning trading, as concerns about future growth outweighed the strength of the Q4 performance.